Tilray Brands (NASDAQ:TLRY) Trading Down 3.6% – Here’s What Happened

Tilray Brands, Inc. (NASDAQ:TLRY)’s share price traded down 3.6% during trading on Tuesday . The company traded as low as $6.79 and last traded at $6.89. 4,183,639 shares traded hands during mid-day trading, an increase of 16% from the average session volume of 3,606,689 shares. The stock had previously closed at $7.15.

Key Headlines Impacting Tilray Brands

Here are the key news stories impacting Tilray Brands this week:

• Positive Sentiment: Federal rescheduling and a consequential tax change (the effective end of 280E for qualifying medical operators) materially improves cash flow for U.S. plant-touching MSOs — a sector-wide financial catalyst that lifted cannabis stocks broadly. The Cannabis Sector’s Billion-Dollar Tax Cut
• Positive Sentiment: Tilray issued statements positioning itself for U.S. expansion and highlighted its medical and beverage businesses as growth levers — management messaging supports a longer-term bull case if U.S. opportunities materialize. Tilray Brands Positioned for U.S. Expansion Amid Historic Cannabis Rescheduling
• Positive Sentiment: Consumer/beverage initiatives (BrewDog USA lineup) highlight diversified revenue streams beyond cannabis, which could help margins and investor perception over time. BrewDog USA Doubles Down on Headliners
• Positive Sentiment: Heavy call-option buying indicates speculative bullish interest that can amplify upside if sentiment reaccelerates. (Options flow reported April 22.)
• Neutral Sentiment: Intraday trading experienced a Limit Up/Limit Down (LULD) pause — a mechanical volatility control that signals high intraday moves but not a new fundamental development.
• Neutral Sentiment: CEO media appearances reiterate the opportunity if U.S. rules loosen, providing color but no immediate revenue impact. Tilray CEO on Possible US Cannabis Reclassification
• Negative Sentiment: “Sell-the-news” reversal and dilution overhang: the initial rally tied to Schedule III headlines faded as traders took profits, and market attention returned to an at-the-market (ATM) equity program (filed earlier in April) that could add supply pressure. Tilray sinks as Schedule III headline turns into a “sell-the-news” reversal
• Negative Sentiment: Insider selling: a director sold ~33,556 shares recently — a signal some investors interpret as caution (though timing and intent can vary). Form 4 — David G. Hopkinson Sale
• Negative Sentiment: Fundamentals still weigh: Tilray’s recent quarter missed EPS estimates and the company remains loss-making with negative margins — investors worry about funding needs and whether newfound policy tailwinds translate quickly into improved earnings for Tilray specifically.

Analyst Ratings Changes

A number of brokerages have recently issued reports on TLRY. Zacks Research raised shares of Tilray Brands from a “strong sell” rating to a “hold” rating in a research report on Wednesday, February 11th. Canaccord Genuity Group began coverage on shares of Tilray Brands in a research note on Tuesday, January 27th. They issued a “hold” rating for the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Tilray Brands in a report on Wednesday, January 21st. Wall Street Zen raised Tilray Brands from a “sell” rating to a “hold” rating in a research report on Saturday, March 21st. Finally, Roth Mkm upgraded Tilray Brands from a “neutral” rating to a “buy” rating and set a $10.00 price objective for the company in a report on Thursday, April 2nd. Three analysts have rated the stock with a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $11.50.

Tilray Brands Stock Performance

The company has a current ratio of 2.79, a quick ratio of 1.66 and a debt-to-equity ratio of 0.19. The company’s fifty day moving average price is $7.03 and its 200-day moving average price is $9.51.

Tilray Brands (NASDAQ:TLRY) last released its earnings results on Wednesday, April 1st. The company reported ($0.24) EPS for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.10). The company had revenue of $206.73 million during the quarter, compared to analyst estimates of $201.35 million. Tilray Brands had a negative return on equity of 3.31% and a negative net margin of 156.51%.During the same quarter last year, the business earned ($0.87) earnings per share. On average, analysts anticipate that Tilray Brands, Inc. will post -0.55 earnings per share for the current fiscal year.

Insider Activity at Tilray Brands

In other news, Director David G. Hopkinson sold 33,556 shares of Tilray Brands stock in a transaction on Tuesday, April 21st. The shares were sold at an average price of $6.94, for a total transaction of $232,878.64. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 0.84% of the company’s stock.

Hedge Funds Weigh In On Tilray Brands

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Apollon Wealth Management LLC acquired a new stake in Tilray Brands during the 1st quarter worth about $96,000. Pictet Asset Management Holding SA raised its stake in shares of Tilray Brands by 38.9% in the first quarter. Pictet Asset Management Holding SA now owns 18,387 shares of the company’s stock worth $119,000 after purchasing an additional 5,145 shares during the last quarter. Alpine Global Management LLC acquired a new stake in shares of Tilray Brands during the fourth quarter worth about $169,000. Voloridge Investment Management LLC purchased a new stake in Tilray Brands in the fourth quarter valued at approximately $824,000. Finally, Polymer Capital Management US LLC purchased a new stake in Tilray Brands in the fourth quarter valued at approximately $1,058,000. Hedge funds and other institutional investors own 9.35% of the company’s stock.

About Tilray Brands

Tilray Brands, Inc is a global cannabis-lifestyle and consumer packaged goods company engaged in the cultivation, production, distribution and sale of cannabis and cannabinoid-based products. The company develops and markets a diverse portfolio of branded products spanning medical cannabis, adult-use recreational products and wellness offerings. Through state-of-the-art cultivation facilities, research and development efforts, and quality control systems, Tilray Brands aims to deliver consistent, scalable products for a range of patient and consumer needs.

Tilray’s product lineup includes cannabis flower, pre-rolls, oils and tinctures, vapes, edibles and topicals, as well as hemp-derived cannabidiol (CBD) products.